Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations

Abstract The COVID-19 pandemic has ushered a globally focused vaccine development program that produced multiple successful vaccines within a year. Four SARS-CoV-2 vaccines have been approved for use in Canada, using two different technologies, all of which have shown excellent efficacy in reducing the rate of symptomatic COVID-19 infection and 100% efficacy in preventing death from COVID-19. People with inflammatory bowel disease (IBD), like many others with immune-mediated chronic diseases, were excluded from the pivotal trials of these vaccines, leading to early hesitancy by regulatory bodies to endorse administering the vaccines to these groups. However, recent data has shown that the adverse event rate to SARS-CoV-2 vaccine among people with IBD is similar to the general population. Early data has further shown that people with IBD are capable of mounting a robust immune response to SARS-CoV-2 vaccines, particularly following a second dose, whereas the response to the first dose is blunted in those receiving anti-TNF therapy or conventional immunosuppressants (azathioprine, 6-mercaptopurine, methotrexate). Based on these data and evidence from previous vaccine programs among people with IBD, multiple national and international expert panels have recommended that individuals with IBD receive complete vaccination against SARS-CoV-2 as soon as possible.

[1]  M. Diamond,et al.  SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses , 2021, Nature.

[2]  N. Mahmud,et al.  Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications , 2021, Gastroenterology.

[3]  H. Sørensen,et al.  Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study , 2021, BMJ.

[4]  Elisabeth Mahase Covid-19: Unusual blood clots are “very rare side effect” of Janssen vaccine, says EMA , 2021, BMJ.

[5]  Andreas Greinacher,et al.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.

[6]  J. Mascola,et al.  Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 , 2021, The New England journal of medicine.

[7]  C. Lees,et al.  Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD , 2021, Gut.

[8]  C. Lees,et al.  Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab , 2021, Gut.

[9]  M. Hernán,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[10]  M. Hayney,et al.  What Gastroenterologists Should Know About COVID-19 Vaccines , 2021, Clinical Gastroenterology and Hepatology.

[11]  P. Moayyedi,et al.  COVID-19 Vaccination in Patients With Inflammatory Bowel Disease: Communiqué From the Canadian Association of Gastroenterology , 2021, Journal of the Canadian Association of Gastroenterology.

[12]  M. Parkes,et al.  SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement , 2021, The Lancet Gastroenterology & Hepatology.

[13]  M. Dubinsky,et al.  SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting , 2021, Gut.

[14]  M. Kappelman,et al.  Reply , 2021, Gastroenterology.

[15]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[16]  Elizabeth B White,et al.  Diverse Functional Autoantibodies in Patients with COVID-19 , 2020, Nature.

[17]  D. Lei,et al.  Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals , 2020, Nature Microbiology.

[18]  V. Tagalakis,et al.  Current estimates of the incidence of acute venous thromboembolic disease in Canada: A meta-analysis. , 2020, Thrombosis research.

[19]  C. Aschwanden The false promise of herd immunity for COVID-19 , 2020, Nature.

[20]  F. Underwood,et al.  Effect of IBD medications on COVID-19 outcomes: results from an international registry , 2020, Gut.

[21]  F. Krammer SARS-CoV-2 vaccines in development , 2020, Nature.

[22]  Kelsey K. Finn,et al.  Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19 , 2020, Cell.

[23]  R. Fouchier,et al.  High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab , 2020, Vaccines.

[24]  S. Ng,et al.  Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry , 2020, Gastroenterology.

[25]  M. Merad,et al.  Immunology of COVID-19: Current State of the Science , 2020, Immunity.

[26]  J. Weinberg,et al.  Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy. , 2018, Inflammatory bowel diseases.

[27]  A. Cheifetz,et al.  Herpes Zoster Vaccine Response in Inflammatory Bowel Disease Patients on Low-dose Immunosuppression , 2016, Inflammatory bowel diseases.

[28]  G. Kaplan,et al.  Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial , 2016, Inflammatory bowel diseases.

[29]  J. Walkowiak,et al.  Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel Disease , 2015, Inflammatory bowel diseases.

[30]  Eun Soo Kim,et al.  Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. , 2014, Journal of Crohn's & colitis.

[31]  B. Feagan,et al.  Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results , 2014, Gut.

[32]  K. Tominaga,et al.  Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. , 2014, Journal of Crohn's & colitis.

[33]  Jin-Ho Kim,et al.  Efficacy of Hepatitis A Vaccination and Factors Impacting on Seroconversion in Patients with Inflammatory Bowel Disease , 2014, Inflammatory bowel diseases.

[34]  K. Papp,et al.  Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. , 2013, Journal of drugs in dermatology : JDD.

[35]  L. Peyrin-Biroulet,et al.  Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study* , 2011, Inflammatory bowel diseases.

[36]  J. Korzenik,et al.  Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease , 2011, Gut.

[37]  S. Targan,et al.  Immunosuppression Impairs Response to Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[38]  A. Bousvaros,et al.  Immune Response to Influenza Vaccine in Children With Inflammatory Bowel Disease , 2009, The American Journal of Gastroenterology.

[39]  Louis J. Cohen,et al.  Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.